{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T03:05:09Z","timestamp":1761102309365,"version":"3.37.3"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Drugs Ther"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1007\/s10557-018-6772-3","type":"journal-article","created":{"date-parts":[[2018,2,28]],"date-time":"2018-02-28T00:34:09Z","timestamp":1519778049000},"page":"47-56","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Safety and Incidence of Cardiovascular Events in Chinese Patients with Acute Coronary Syndrome Treated with Ticagrelor: the 12-Month, Phase IV, Multicenter, Single-Arm DAYU Study"],"prefix":"10.1007","volume":"32","author":[{"name":"on behalf of the DAYU study investigators","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Runlin","family":"Gao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yongjian","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hengliang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guohai","family":"Su","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zuyi","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aidong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhirong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huanyi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lijun","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Leonsson-Zachrisson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yaling","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,2,28]]},"reference":[{"key":"6772_CR1","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.ijcard.2015.06.170","volume":"6","author":"H Li","year":"2015","unstructured":"Li H, Ge J. Cardiovascular disease in China: current status and future perspectives. Int J Cardiol Heart Vasc. 2015;6:25\u201331.","journal-title":"Int J Cardiol Heart Vasc"},{"key":"6772_CR2","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1016\/j.ijcard.2015.04.073","volume":"202","author":"MY Chan","year":"2016","unstructured":"Chan MY, Du X, Eccleston D, et al. Acute coronary syndrome in the Asia-Pacific region. Int J Cardiol. 2016;202:861\u20139.","journal-title":"Int J Cardiol"},{"issue":"13","key":"6772_CR3","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/S0735-1097(16)30506-X","volume":"67","author":"Y Huo","year":"2016","unstructured":"Huo Y, Han YL, Ge J, et al. Two-year outcomes post discharge in Chinese patients with acute coronary syndrome: findings from the EPICOR Asia study. J Am Coll Cardiol. 2016;67(13):505.","journal-title":"J Am Coll Cardiol"},{"issue":"8","key":"6772_CR4","first-page":"611","volume":"53","author":"W Wang","year":"2014","unstructured":"Wang W, Zhao D, Liu J, Qi Y, Sun J, Liu J. The prevalence of risk factors and status of clinical practice patterns among hospitalized patients with acute coronary syndromes. Zhonghua Nei Ke Za Zhi. 2014;53(8):611\u20136.","journal-title":"Zhonghua Nei Ke Za Zhi"},{"issue":"4","key":"6772_CR5","doi-asserted-by":"publisher","first-page":"e362","DOI":"10.1161\/CIR.0b013e3182742c84","volume":"127","author":"PT O'Gara","year":"2013","unstructured":"O'Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF\/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines. Circulation. 2013;127(4):e362\u2013425.","journal-title":"Circulation"},{"issue":"20","key":"6772_CR6","doi-asserted-by":"publisher","first-page":"2569","DOI":"10.1093\/eurheartj\/ehs215","volume":"33","author":"PG Steg","year":"2012","unstructured":"Steg PG, James SK, Atar D, et al. ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J. 2012;33(20):2569\u2013619.","journal-title":"Eur Heart J"},{"issue":"25","key":"6772_CR7","doi-asserted-by":"publisher","first-page":"2354","DOI":"10.1161\/CIR.0000000000000133","volume":"130","author":"EA Amsterdam","year":"2014","unstructured":"Amsterdam EA, Wenger NK, Brindis RG, et al. 2014 AHA\/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: executive summary: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;130(25):2354\u201394.","journal-title":"Circulation"},{"issue":"3","key":"6772_CR8","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1093\/eurheartj\/ehv320","volume":"37","author":"M Roffi","year":"2016","unstructured":"Roffi M, Patrono C, Collet JP, et al. 2015 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). Eur Heart J. 2016;37(3):267\u2013315.","journal-title":"Eur Heart J"},{"issue":"5","key":"6772_CR9","first-page":"380","volume":"43","author":"China Society of Cardiology of Chinese Medical Association","year":"2015","unstructured":"China Society of Cardiology of Chinese Medical Association. Guideline on the diagnosis and therapy of ST-segment elevation myocardial infarction. Zhonghua Xin Xue Guan Bing Za Zhi. 2015;43(5):380\u201393.","journal-title":"Zhonghua Xin Xue Guan Bing Za Zhi"},{"issue":"4","key":"6772_CR10","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1111\/j.1755-5922.2009.00096.x","volume":"27","author":"S Husted","year":"2009","unstructured":"Husted S, van Giezen JJ. Ticagrelor: the first reversibly binding oral P2Y12 receptor antagonist. Cardiovasc Ther. 2009;27(4):259\u201374.","journal-title":"Cardiovasc Ther"},{"issue":"9","key":"6772_CR11","doi-asserted-by":"publisher","first-page":"1556","DOI":"10.1111\/j.1538-7836.2009.03527.x","volume":"7","author":"JJ Giezen van","year":"2009","unstructured":"van Giezen JJ, Nilsson L, Berntsson P, et al. Ticagrelor binds to human P2Y(12) independently from ADP but antagonizes ADP-induced receptor signaling and platelet aggregation. J Thromb Haemost. 2009;7(9):1556\u201365.","journal-title":"J Thromb Haemost"},{"issue":"2","key":"6772_CR12","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1177\/1074248413511693","volume":"19","author":"D Armstrong","year":"2014","unstructured":"Armstrong D, Summers C, Ewart L, Nylander S, Sidaway JE, van Giezen JJ. Characterization of the adenosine pharmacology of ticagrelor reveals therapeutically relevant inhibition of equilibrative nucleoside transporter 1. J Cardiovasc Pharmacol Ther. 2014;19(2):209\u201319.","journal-title":"J Cardiovasc Pharmacol Ther"},{"unstructured":"AstraZeneca LP. Brilinta (ticagrelor) tablets. Approved US prescribing information. Revised September 2016. Available at: http:\/\/www.azpicentral.com\/brilinta\/brilinta.pdf . Accessed 23 Oct 2017.","key":"6772_CR13"},{"issue":"11","key":"6772_CR14","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","volume":"361","author":"L Wallentin","year":"2009","unstructured":"Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361(11):1045\u201357.","journal-title":"N Engl J Med"},{"issue":"19","key":"6772_CR15","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1056\/NEJMoa1500857","volume":"372","author":"MP Bonaca","year":"2015","unstructured":"Bonaca MP, Bhatt DL, Cohen M, et al. Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med. 2015;372(19):1791\u2013800.","journal-title":"N Engl J Med"},{"issue":"6","key":"6772_CR16","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1016\/j.ahj.2015.03.015","volume":"169","author":"HJ Kang","year":"2015","unstructured":"Kang HJ, Clare RM, Gao R, et al. Ticagrelor versus clopidogrel in Asian patients with acute coronary syndrome: a retrospective analysis from the Platelet Inhibition and Patient Outcomes (PLATO) Trial. Am Heart J. 2015;169(6):899\u2013905.","journal-title":"Am Heart J"},{"issue":"10","key":"6772_CR17","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1038\/nrcardio.2014.104","volume":"11","author":"GN Levine","year":"2014","unstructured":"Levine GN, Jeong YH, Goto S, et al. Expert consensus document: World Heart Federation expert consensus statement on antiplatelet therapy in East Asian patients with ACS or undergoing PCI. Nat Rev Cardiol. 2014;11(10):597\u2013606.","journal-title":"Nat Rev Cardiol"},{"issue":"7","key":"6772_CR18","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1097\/FPC.0b013e3283385420","volume":"20","author":"K Sangkuhl","year":"2010","unstructured":"Sangkuhl K, Klein TE, Altman RB. Clopidogrel pathway. Pharmacogenet Genomics. 2010;20(7):463\u20135.","journal-title":"Pharmacogenet Genomics"},{"issue":"4","key":"6772_CR19","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1111\/j.1365-2125.2011.03949.x","volume":"72","author":"TKW Ma","year":"2011","unstructured":"Ma TKW, Lam Y-Y, Tan VP, Yan BP. Variability in response to clopidogrel: how important are pharmacogenetics and drug interactions? Br J Clin Pharmacol. 2011;72(4):697\u2013706.","journal-title":"Br J Clin Pharmacol"},{"doi-asserted-by":"crossref","unstructured":"Guo YM, Zhao ZC, Zhang L, Li HZ, Sun HL. CYP2C19 polymorphisms in acute coronary syndrome patients undergoing clopidogrel therapy in Zhengzhou population. Genet Mol Res. 2016;15(2).","key":"6772_CR20","DOI":"10.4238\/gmr.15028012"},{"issue":"3","key":"6772_CR21","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0059344","volume":"8","author":"X Xie","year":"2013","unstructured":"Xie X, Ma YT, Yang YN, et al. CYP2C19 phenotype, stent thrombosis, myocardial infarction, and mortality in patients with coronary stent placement in a Chinese population. PLoS One. 2013;8(3):e59344.","journal-title":"PLoS One"},{"issue":"1","key":"6772_CR22","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1177\/0300060516677190","volume":"45","author":"CC Tam","year":"2017","unstructured":"Tam CC, Kwok J, Wong A, et al. Genotyping-guided approach versus the conventional approach in selection of oral P2Y12 receptor blockers in Chinese patients suffering from acute coronary syndrome. J Int Med Res. 2017;45(1):134\u201346.","journal-title":"J Int Med Res"},{"issue":"2","key":"6772_CR23","doi-asserted-by":"publisher","first-page":"87","DOI":"10.2165\/11595930-000000000-00000","volume":"32","author":"H Li","year":"2012","unstructured":"Li H, Butler K, Yang L, Yang Z, Teng R. Pharmacokinetics and tolerability of single- and multiple-doses of ticagrelor in healthy Chinese volunteers. Clin Drug Investig. 2012;32(2):87\u201397.","journal-title":"Clin Drug Investig"},{"issue":"6","key":"6772_CR24","doi-asserted-by":"publisher","first-page":"478","DOI":"10.5414\/CP202017","volume":"52","author":"R Teng","year":"2014","unstructured":"Teng R, Butler K. Pharmacokinetics, pharmacodynamics, and tolerability of single and multiple doses of ticagrelor in Japanese and Caucasian volunteers. Int J Clin Pharmacol Ther. 2014;52(6):478\u201391.","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"4","key":"6772_CR25","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1007\/s12928-014-0277-1","volume":"29","author":"Y Hiasa","year":"2014","unstructured":"Hiasa Y, Teng R, Emanuelsson H. Pharmacodynamics, pharmacokinetics and safety of ticagrelor in Asian patients with stable coronary artery disease. Cardiovasc Interv Ther. 2014;29(4):324\u201333.","journal-title":"Cardiovasc Interv Ther"},{"issue":"2","key":"6772_CR26","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1111\/bcp.12950","volume":"82","author":"H Li","year":"2016","unstructured":"Li H, Guo J, Carlson GF, Teng R. Pharmacodynamics, pharmacokinetics, and safety of ticagrelor in Chinese patients with stable coronary heart disease. Br J Clin Pharmacol. 2016;82(2):352\u201361.","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"6772_CR27","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/j.ahj.2009.01.003","volume":"157","author":"S James","year":"2009","unstructured":"James S, Akerblom A, Cannon CP, et al. Comparison of ticagrelor, the first reversible oral P2Y(12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial. Am Heart J. 2009;157(4):599\u2013605.","journal-title":"Am Heart J"},{"issue":"2","key":"6772_CR28","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1136\/heartjnl-2016-309509","volume":"103","author":"H Bueno","year":"2017","unstructured":"Bueno H, Pocock S, Danchin N, et al. International patterns of dual antiplatelet therapy duration after acute coronary syndromes. Heart. 2017;103(2):132\u20138.","journal-title":"Heart"},{"issue":"12","key":"6772_CR29","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1161\/CIRCRESAHA.114.302737","volume":"114","author":"DL Bhatt","year":"2014","unstructured":"Bhatt DL, Hulot JS, Moliterno DJ, Harrington RA. Antiplatelet and anticoagulation therapy for acute coronary syndromes. Circ Res. 2014;114(12):1929\u201343.","journal-title":"Circ Res"},{"issue":"11","key":"6772_CR30","doi-asserted-by":"publisher","first-page":"2452","DOI":"10.1253\/circj.CJ-15-0112","volume":"79","author":"S Goto","year":"2015","unstructured":"Goto S, Huang CH, Park SJ, Emanuelsson H, Kimura T. Ticagrelor vs. clopidogrel in Japanese, Korean and Taiwanese patients with acute coronary syndrome - randomized, double-blind, phase III PHILO study. Circ J. 2015;79(11):2452\u201360.","journal-title":"Circ J"},{"issue":"2","key":"6772_CR31","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1038\/clpt.2011.223","volume":"91","author":"K Butler","year":"2012","unstructured":"Butler K, Teng R. Evaluation and characterization of the effects of ticagrelor on serum and urinary uric acid in healthy volunteers. Clin Pharmacol Ther. 2012;91(2):264\u201371.","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"6772_CR32","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1056\/NEJMoa1603060","volume":"375","author":"S Johnston","year":"2016","unstructured":"Johnston S, Amarenco P, Albers G, et al. Ticagrelor versus aspirin in acute stroke or transient ischemic attack. N Engl J Med. 2016;375(1):35\u201343.","journal-title":"N Engl J Med"},{"issue":"1","key":"6772_CR33","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1056\/NEJMoa1611688","volume":"376","author":"WR Hiatt","year":"2017","unstructured":"Hiatt WR, Fowkes GR, Heizer G, et al. Ticagrelor versus clopidogrel in symptomatic peripheral artery disease. N Engl J Med. 2017;376(1):32\u201340.","journal-title":"N Engl J Med"}],"container-title":["Cardiovascular Drugs and Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10557-018-6772-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-018-6772-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-018-6772-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,14]],"date-time":"2022-08-14T23:53:16Z","timestamp":1660521196000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10557-018-6772-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,2]]}},"alternative-id":["6772"],"URL":"https:\/\/doi.org\/10.1007\/s10557-018-6772-3","relation":{},"ISSN":["0920-3206","1573-7241"],"issn-type":[{"type":"print","value":"0920-3206"},{"type":"electronic","value":"1573-7241"}],"subject":[],"published":{"date-parts":[[2018,2]]},"assertion":[{"value":"28 February 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"RG received a research grant from AstraZeneca. HL, YWu, GS, Yan W, ZW, HZ, AZ, YZ, Yong W, ZY, and YH declare no conflicts of interest. LL and ML-Z are current employees of AstraZeneca. LS was an employee of AstraZeneca when the study was conducted.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki and the International Conference on Harmonization\/Good Clinical Practice Guidelines, and followed applicable regulatory requirements including AstraZeneca\u2019s policy on bioethics. The local Institutional Review Boards or Independent Ethics Committees approved the final protocol and amendment. Written informed consent was obtained from all patients.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}